GeneDx Holdings Corp Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
5-Yr Fwd EPS Growth
9.5%projected annual EPS growth
Analyst Coverage
9analysts covering
FY Revenue (est.)
$481.6Mnext fiscal year
FY EPS (est.)
$0.13next fiscal year
Reporting Calendar
| Event | Expected Date |
|---|---|
| Q3 2026 Earnings Release | 27 Oct 2026 |
Monitoring Framework
Key Performance Indicators
Exome and Genome Test Result Volume Quarterly27.5KTarget: At least 30% year-over-year growth for FY 2026 (approx. 126,400 tests)
Blended Average Reimbursement Rate (ARR) Quarterly3.3KTarget: Stabilization and recovery from Q100 2026 drop%
Adjusted Gross Margin Quarterly69.0%Target: Approximately 70% for FY 2026
Total Revenue Quarterly102.3MTarget: $475 million to $490 million for FY 2026
Watch Items
- Securities Class Action LitigationTrigger: August 3, 2026 Lead Plaintiff DeadlineAction: Monitor court filings, legal defense costs, and potential impact on investor sentiment and corporate reputation.
- Payer Mix and Reimbursement PressuresTrigger: Blended ARR falling below $3,300Action: Evaluate the effectiveness of the newly launched Exome-to-Genome Reflex product and revenue cycle management AI tools.
- Fabric Genomics Integration and Write-downsTrigger: Further impairment of remaining goodwill or international market underperformanceAction: Assess international commercialization progress and restructuring of the Fabric Genomics unit following the $31.3 million Q1 2026 impairment.
Research as of 20 Jun 2026